Role of Radiomics in the Everolimus response prediction of metastatic neuroendocrine tumors

#3439

Introduction: Radiomics was shown to provide non-invasive imaging biomarkers predicting prognosis and treatment response.

Aim(s): To investigate performance of Radiomics to predict progression free survival (PFS) and overall survival (OS) in patients with neuroendocrine tumors (NETs) treated with Everolimus.

Materials and methods: This is a retrospective study including patients with metastatic gastro-enter-pancreatic (GEP) NETs who underwent to a contrast enhanced (CT) at baseline and the end of Everolimus therapy. All patients were divided into two groups: Good- and non-responder according to PFS>12 or < 12 months. A dedicated software was used to extract texture parameters of first and second order. Textural parameters performance in the prediction of response to therapy was assessed with Receiver Operating Characteristic (ROC) curve correlated with baseline CT and PFS; performance of texture analysis to predict OS was tested with ROC curve between delta textural parameters (pre and post therapy) and OS.

Conference:

Presenting Author: Magi L

Authors: Magi L, Polici M, Zerunian M, Rinzivillo M, Marasco M,

Keywords: response to treatment, Everolimus, neuroendocrine tumor, Radiomics, targeted therapy,